Sheppard | Jotup

BlueHalo Bolsters Leading Position in Counter-UAS With Acquisition of Verus Technology Group

Retrieved on:

星期一, 四月 3, 2023

ARLINGTON, Va., April 3, 2023 /PRNewswire/ -- BlueHalo, a leading provider of critical capabilities and technologies across Space, Air, and Cyber domains, today announced it has acquired Verus Technology Group, Inc. ("Verus" or the "Company").

Key Points:

ARLINGTON, Va., April 3, 2023 /PRNewswire/ -- BlueHalo, a leading provider of critical capabilities and technologies across Space, Air, and Cyber domains, today announced it has acquired Verus Technology Group, Inc. ("Verus" or the "Company").
Founded in 2014, Verus designs, develops, and integrates counter-Unmanned Aerial Systems ("c-UAS") products utilizing industry-leading radio frequency ("RF") and digital signal processing ("DSP") technologies.
We're thrilled to continue to push boundaries and deliver critical technology and capabilities to the warfighter with BlueHalo."
Citizens Capital Markets acted as sole financial adviser and Cooley LLP served as legal counsel to Verus Technology Group.

Biological Dynamics and Oregon Health & Science University Collaborate on Early-Stage Pancreatic Cancer Detection Study

Retrieved on:

星期三, 三月 1, 2023

Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.

Key Points:

Biological Dynamics, Inc. , a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University (OHSU) to study its ExoVita™ Pancreas assay.
The Brenden-Colson Center has a robust, integrated clinical-translational interface to drive innovative patient care and nourish scientific collaborations.
The ExoVita Pancreas assay significantly improves the care of patients at high risk for pancreatic cancer through earlier detection.
“We have a long-standing relationship with Oregon Health & Science University and look forward to collaborating to evaluate the clinical validity of our ExoVita Pancreas test,” said Paul Billings, MD, PhD, CEO of Biological Dynamics.

Colgate Women’s Games Returns for 48th Season

Retrieved on:

星期四, 二月 16, 2023

View the full release here: https://www.businesswire.com/news/home/20230215005748/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20230215005748/en/
Also today, Colgate is announcing ShopRite is a supporter for the 48th season of Colgate Women’s Games.
ShopRite plans to host a New Jersey registration event in April that will include a pep rally, celebrating the local community's participation in Colgate Women’s Games.
The health and safety of athletes and spectators are the top priority of Colgate Women’s Games.
For more information on Colgate Women’s Games and to sign up for updates, visit www.ColgateWomensGames.com .

Pryor Cashman Welcomes Three New Partners to Expand Its Media + Entertainment Practice

Retrieved on:

星期一, 二月 6, 2023

Legal, Other Communications, Entertainment, Consulting, Communications, Professional Services, Media, General Entertainment, Other Professional Services, Gerard Debaets, Lawyer, Acquisition, Film, Sheppard, Shanghai Media & Entertainment Group, Television, Music

Pryor Cashman is pleased to announce that Briana Hill , Simon Pulman , and Amy Stein Simonds have joined the firm as partners in the Media + Entertainment Group.

Key Points:

Pryor Cashman is pleased to announce that Briana Hill , Simon Pulman , and Amy Stein Simonds have joined the firm as partners in the Media + Entertainment Group.
She also works with videogame publishers, toy brands, and other nontraditional entertainment clients to help them structure and navigate entertainment industry deals.
“These three talented lawyers invigorate our already important media and film practice,” said Ronald Shechtman , Managing Partner of Pryor Cashman.
“We can’t think of a better place to build and expand our practice than Pryor Cashman,” said Briana.

Delfi Hires Lee-Ann Smith-Freeman as Vice President of Legal

Retrieved on:

星期四, 二月 16, 2023

Patent, Delfi, Intellectual property, Santa Clara University School of Law, Patient, University, PALO, Doctor of Philosophy, Associate, Twist Bioscience, Sheppard, Marketing, Cancer, Management, Nursing, Chemistry, Law, MD

BALTIMORE and PALO ALTO, Calif., Feb. 16, 2023 /PRNewswire/ -- Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, hired Lee-Ann Smith-Freeman, PhD., as its first Vice President of Legal.

Key Points:

BALTIMORE and PALO ALTO, Calif., Feb. 16, 2023 /PRNewswire/ -- Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, hired Lee-Ann Smith-Freeman, PhD., as its first Vice President of Legal.
Lee-Ann most recently served as Associate General Counsel at Twist Bioscience, handling intellectual property, commercial, marketing and procurement legal matters.
She earned her Ph.D. from the University of Southern California and her J.D.
"I am excited to join Delfi's leadership team and help bring this unique technology platform to patients around the world," Smith-Freeman said.

LAXAI Receives Investment from SIGNET Healthcare Partners

Retrieved on:

星期一, 十月 24, 2022

LAXAI Inc. (LAXAI) announced today that it has received a growth capital investment from SIGNET Healthcare Partners (SIGNET), a New York-based healthcare private equity firm.

Key Points:

LAXAI Inc. (LAXAI) announced today that it has received a growth capital investment from SIGNET Healthcare Partners (SIGNET), a New York-based healthcare private equity firm.
This significant equity investment from SIGNET aims to provide LAXAI with a long-term, well-capitalized financial partner that will support LAXAIs growth strategy.
SIGNETs investment will enhance LAXAIs infrastructure and further augment operations to help our customers and partners maximize innovation and productivity.
As an active investor, SIGNET partners closely with its companies to build their value including facilitating activities between portfolio companies.

Majesco Acquires Global IQX Bringing Unmatched Underwriting Workbench, Enrollment and Artificial Intelligence Solutions to the L&AH Industry

Retrieved on:

星期一, 十月 3, 2022

Majesco adds sixteen customers as well as a powerful underwriting workbench, and enrollment & artificial intelligence solutions to their market leading core and absence management solutions.

Key Points:

Majesco adds sixteen customers as well as a powerful underwriting workbench, and enrollment & artificial intelligence solutions to their market leading core and absence management solutions.
Global IQX market leading solutions combined with our core and absence solutions will provide the L&AH insurance market with some of the most robust, innovative solutions.
The combined solution portfolio of Global IQX and Majesco will elevate underwriting and enrollment capabilities, with AI capabilities that give insurers a competitive edge both strategically and operationally.
Global IQX will be pre-integrated with Majesco Policy for L&AH and will continue to integrate with other policy solutions as needed by customers.

Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting

Retrieved on:

星期一, 九月 26, 2022

VAUGHAN, ON, Sept. 26, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that seven scientific podium and poster presentations involving its products and pipeline, as well as data from the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the American Academy of Ophthalmology (AAO), which will take place in Chicago from Sept. 30 to Oct. 3, 2022.

Key Points:

"Suprachoroidal Triamcinolone Acetonide for Macular Edema Associated with Uveitis: Outcomes by Various Uveitis Subtypes in PEACHTREE."
"Suprachoroidal Use of Triamcinolone Acetonide: A Post-Hoc Analysis of PEACHTREE to Evaluate Elevations in Intraocular Pressure."
"Efficacy of Suprachoroidal Triamcinolone Acetonide in the Treatment of Uveitic Macular Edema in Patients with Earlier vs. Later Disease."
*LUCENTIS is a registered trademark of Genentech Inc.
/TM aretrademarks of Bausch & Lomb Incorporated or its affiliates.

Kustom Announces New Chief Operating Officer, Strengthens Operating Model to Support Future Growth

Retrieved on:

星期一, 九月 19, 2022

Clean Harbors, Suffolk University, Creativity, CEO, Culture, Bias, COO, Republic Services, Sale, Sheppard, Management, Kustom

LONGWOOD, Fla., Sept. 19, 2022 /PRNewswire/ -- Today, Kustom the largest privately-owned, full-service restoration company in North America, announces the appointment of Kevin Sheppard as Chief Operating Officer. As the new strategic leader of people and processes, Kevin will report directly to Chief Executive Officer, Andrew Zavodney and be responsible for deepening the institutional mindset that is already engrained in the culture at Kustom by virtue of a customer and employee-centric operating model.

Key Points:

LONGWOOD, Fla., Sept. 19, 2022 /PRNewswire/ -- Today, Kustom the largest privately-owned, full-service restoration company in North America, announces the appointment of Kevin Sheppard as Chief Operating Officer.
Before joining Kustom, Kevin spent the entirety of his professional career in the environmental services space.
I'm eager to see what we can accomplish together as the remainder of this year unfolds," states Andrew Zavodney, CEO at Kustom.
"To say I'm bullish and enthusiastic about the future of Kustom and what this team can accomplish would be an understatement."

Greenbacker secures $186 million credit agreement with KeyBank and Fifth Third Bank

Retrieved on:

星期四, 九月 15, 2022

NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Greenbacker Renewable Energy Company LLC (GREC or Greenbacker), a leading green energy investment company and independent power producer, has entered into a senior credit agreement of $186.2 million with KeyBank N.A.

Key Points:

NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Greenbacker Renewable Energy Company LLC (GREC or Greenbacker), a leading green energy investment company and independent power producer, has entered into a senior credit agreement of $186.2 million with KeyBank N.A.
KeyBank served as administrative agent for the lenders, and KeyBanc Capital Markets and Fifth Third Bank, National Association served as joint lead arrangers.
"We're thrilled to partner with KeyBank and Fifth Third Bank on this senior credit agreement to build projects that will drive a clean energy future in a very real way, said Spencer Mash, CFO of GREC.
Fifth Third Banks commitment to financing renewable energy technologies is well-known and steadfast, said Kyle Kuhn, Renewable Energy Executive Director, Fifth Third Bank.